tiprankstipranks
Biohaven Ltd. (BHVN)
NYSE:BHVN
US Market
BHVN
Biohaven Ltd.
RESEARCH TOOLSreports

Biohaven Ltd. (BHVN) Stock Forecast & Price Target

847 Followers
See the Price Targets and Ratings of:

BHVN Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
7 Buy
3 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Biohaven
Ltd.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BHVN Stock 12 Month Forecast

Average Price Target

$21.50
▲(119.39% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Biohaven Ltd. in the last 3 months. The average price target is $21.50 with a high forecast of $30.00 and a low forecast of $10.00. The average price target represents a 119.39% change from the last price of $9.80.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","31":"$31","13.75":"$13.75","19.5":"$19.5","25.25":"$25.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,13.75,19.5,25.25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.62,11.187692307692307,12.755384615384616,14.323076923076922,15.89076923076923,17.45846153846154,19.026153846153846,20.593846153846155,22.161538461538463,23.72923076923077,25.29692307692308,26.864615384615384,28.432307692307695,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.62,10.533846153846152,11.447692307692307,12.36153846153846,13.275384615384615,14.189230769230768,15.103076923076923,16.016923076923078,16.93076923076923,17.844615384615384,18.75846153846154,19.67230769230769,20.586153846153845,{"y":21.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.62,9.649230769230769,9.678461538461537,9.707692307692307,9.736923076923077,9.766153846153845,9.795384615384615,9.824615384615385,9.853846153846154,9.883076923076922,9.912307692307692,9.941538461538462,9.97076923076923,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.32,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.29,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.81,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 63, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.62,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$21.50Lowest Price Target$10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on BHVN
Samantha Semenkow
Citi
Citi
$14→$17
Buy
73.47%
Upside
Reiterated
04/02/26
Biohaven price target raised to $17 from $14 at CitiBiohaven price target raised to $17 from $14 at Citi
Piper Sandler Analyst forecast on BHVN
Allison Bratzel
Piper Sandler
Piper Sandler
$30
Buy
206.12%
Upside
Reiterated
03/24/26
Biohaven Ltd. (BHVN) Gets a Buy from Piper Sandler
TD Cowen Analyst forecast on BHVN
Tyler Van Buren
TD Cowen
TD Cowen
$15→$30
Buy
206.12%
Upside
Assigned
03/11/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX), Biohaven Ltd. (NYSE: BHVN) and Siemens Healthineers AG (Other OTC: SEMHF)
RBC Capital Analyst forecast on BHVN
Leonid Timashev
RBC Capital
RBC Capital
$23
Buy
134.69%
Upside
Reiterated
03/11/26
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Allogene Therapeutics (ALLO)
Goldman Sachs Analyst forecast on BHVN
Corinne Johnson
Goldman Sachs
Goldman Sachs
$24→$27
Buy
175.51%
Upside
Reiterated
03/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Biohaven Ltd. (NYSE: BHVN) and Teladoc (NYSE: TDOC)
Morgan Stanley Analyst forecast on BHVN
Terence Flynn
Morgan Stanley
Morgan Stanley
$21
Buy
114.29%
Upside
Reiterated
03/09/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Raymond James Analyst forecast on BHVN
Christopher Raymond
Raymond James
Raymond James
―
Buy
―
Reiterated
03/09/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bank of America Securities Analyst forecast on BHVN
Dina Ramadane
Bank of America Securities
Bank of America Securities
$14
Hold
42.86%
Upside
Reiterated
03/09/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (NASDAQ: ATAI), BridgeBio Oncology Therapeutics (NASDAQ: BBOT) and Biohaven Ltd. (NYSE: BHVN)
H.C. Wainwright Analyst forecast on BHVN
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$10
Hold
2.04%
Upside
Assigned
03/08/26
Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (NYSE: BHVN) and Atai Beckley N.V. (NASDAQ: ATAI)
William Blair Analyst forecast on BHVN
Myles Minter
William Blair
William Blair
―
Hold
―
Reiterated
03/03/26
Maintaining Hold on Biohaven: Encouraging Early Signals but Awaiting Placebo-Controlled Data and Funding Clarity
J.P. Morgan Analyst forecast on BHVN
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
12/26/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Novavax (NASDAQ: NVAX), Xenon (NASDAQ: XENE) and Biohaven Ltd. (NYSE: BHVN)
Leerink Partners Analyst forecast on BHVN
Marc Goodman
Leerink Partners
Leerink Partners
$50→$15
Buy
53.06%
Upside
Reiterated
12/25/25
Biohaven: MDD Setback but Epilepsy Refocus and Diversified Pipeline Support Continued Buy Rating
UBS Analyst forecast on BHVN
Ashwani Verma
UBS
UBS
$26→$11
Hold
12.24%
Upside
Downgraded
11/28/25
Cautious Hold Rating on Biohaven Ltd. Amidst R&D Setbacks and Competitive Challenges
BTIG Analyst forecast on BHVN
Thomas Shrader
BTIG
BTIG
$16
Buy
63.27%
Upside
Reiterated
11/17/25
Strategic Positioning and Growth Potential Drive Buy Rating for Biohaven Ltd.
Bernstein Analyst forecast on BHVN
William Pickering
Bernstein
Bernstein
$34→$9
Hold
-8.16%
Downside
Downgraded
11/06/25
Hold Rating on Biohaven Ltd. Amid Liquidity Challenges and Uncertain Clinical Outcomes
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on BHVN
Samantha Semenkow
Citi
Citi
$14→$17
Buy
73.47%
Upside
Reiterated
04/02/26
Biohaven price target raised to $17 from $14 at CitiBiohaven price target raised to $17 from $14 at Citi
Piper Sandler Analyst forecast on BHVN
Allison Bratzel
Piper Sandler
Piper Sandler
$30
Buy
206.12%
Upside
Reiterated
03/24/26
Biohaven Ltd. (BHVN) Gets a Buy from Piper Sandler
TD Cowen Analyst forecast on BHVN
Tyler Van Buren
TD Cowen
TD Cowen
$15→$30
Buy
206.12%
Upside
Assigned
03/11/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX), Biohaven Ltd. (NYSE: BHVN) and Siemens Healthineers AG (Other OTC: SEMHF)
RBC Capital Analyst forecast on BHVN
Leonid Timashev
RBC Capital
RBC Capital
$23
Buy
134.69%
Upside
Reiterated
03/11/26
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Allogene Therapeutics (ALLO)
Goldman Sachs Analyst forecast on BHVN
Corinne Johnson
Goldman Sachs
Goldman Sachs
$24→$27
Buy
175.51%
Upside
Reiterated
03/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Biohaven Ltd. (NYSE: BHVN) and Teladoc (NYSE: TDOC)
Morgan Stanley Analyst forecast on BHVN
Terence Flynn
Morgan Stanley
Morgan Stanley
$21
Buy
114.29%
Upside
Reiterated
03/09/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Raymond James Analyst forecast on BHVN
Christopher Raymond
Raymond James
Raymond James
―
Buy
―
Reiterated
03/09/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bank of America Securities Analyst forecast on BHVN
Dina Ramadane
Bank of America Securities
Bank of America Securities
$14
Hold
42.86%
Upside
Reiterated
03/09/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (NASDAQ: ATAI), BridgeBio Oncology Therapeutics (NASDAQ: BBOT) and Biohaven Ltd. (NYSE: BHVN)
H.C. Wainwright Analyst forecast on BHVN
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$10
Hold
2.04%
Upside
Assigned
03/08/26
Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (NYSE: BHVN) and Atai Beckley N.V. (NASDAQ: ATAI)
William Blair Analyst forecast on BHVN
Myles Minter
William Blair
William Blair
―
Hold
―
Reiterated
03/03/26
Maintaining Hold on Biohaven: Encouraging Early Signals but Awaiting Placebo-Controlled Data and Funding Clarity
J.P. Morgan Analyst forecast on BHVN
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
12/26/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Novavax (NASDAQ: NVAX), Xenon (NASDAQ: XENE) and Biohaven Ltd. (NYSE: BHVN)
Leerink Partners Analyst forecast on BHVN
Marc Goodman
Leerink Partners
Leerink Partners
$50→$15
Buy
53.06%
Upside
Reiterated
12/25/25
Biohaven: MDD Setback but Epilepsy Refocus and Diversified Pipeline Support Continued Buy Rating
UBS Analyst forecast on BHVN
Ashwani Verma
UBS
UBS
$26→$11
Hold
12.24%
Upside
Downgraded
11/28/25
Cautious Hold Rating on Biohaven Ltd. Amidst R&D Setbacks and Competitive Challenges
BTIG Analyst forecast on BHVN
Thomas Shrader
BTIG
BTIG
$16
Buy
63.27%
Upside
Reiterated
11/17/25
Strategic Positioning and Growth Potential Drive Buy Rating for Biohaven Ltd.
Bernstein Analyst forecast on BHVN
William Pickering
Bernstein
Bernstein
$34→$9
Hold
-8.16%
Downside
Downgraded
11/06/25
Hold Rating on Biohaven Ltd. Amid Liquidity Challenges and Uncertain Clinical Outcomes
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biohaven Ltd.

3 Months
xxx
Success Rate
10/22 ratings generated profit
45%
Average Return
+6.10%
reiterated a xxx
 rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +6.10% per trade.
1 Year
Thomas ShraderBTIG
Success Rate
10/22 ratings generated profit
45%
Average Return
+19.58%
reiterated a buy rating 5 months ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +19.58% per trade.
2 Years
xxx
Success Rate
5/22 ratings generated profit
23%
Average Return
-27.32%
reiterated a xxx
 rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 22.73% of your transactions generating a profit, with an average return of -27.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BHVN Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
16
15
4
10
10
Buy
4
5
5
3
2
Hold
11
43
36
63
40
Sell
0
2
2
15
16
Strong Sell
0
0
0
0
0
total
31
65
47
91
68
In the current month, BHVN has received 12 Buy Ratings, 40 Hold Ratings, and 16 Sell Ratings. BHVN average Analyst price target in the past 3 months is 21.50.
Each month's total comprises the sum of three months' worth of ratings.

BHVN Financial Forecast

BHVN Earnings Forecast

Next quarter’s earnings estimate for BHVN is -$0.84 with a range of -$1.15 to -$0.61. The previous quarter’s EPS was -$1.21. BHVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.
Next quarter’s earnings estimate for BHVN is -$0.84 with a range of -$1.15 to -$0.61. The previous quarter’s EPS was -$1.21. BHVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.
No data currently available

BHVN Sales Forecast

Next quarter’s sales forecast for BHVN is $294.00K with a range of $0.00 to $2.94M. The previous quarter’s sales results were $0.00. BHVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.
Next quarter’s sales forecast for BHVN is $294.00K with a range of $0.00 to $2.94M. The previous quarter’s sales results were $0.00. BHVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.

BHVN Stock Forecast FAQ

What is BHVN’s average 12-month price target, according to analysts?
Based on analyst ratings, Biohaven Ltd.’s 12-month average price target is 21.50.
    What is BHVN’s upside potential, based on the analysts’ average price target?
    Biohaven Ltd. has 119.39% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BHVN a Buy, Sell or Hold?
          Biohaven Ltd. has a consensus rating of Moderate Buy which is based on 7 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Biohaven Ltd.’s price target?
            The average price target for Biohaven Ltd. is 21.50. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $10.00. The average price target represents 119.39% Increase from the current price of $9.8.
              What do analysts say about Biohaven Ltd.?
              Biohaven Ltd.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of BHVN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.